All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer : a phase II study
Joint Authors
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 26, Issue 4 (31 Dec. 2014), pp.187-194, 8 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2014-12-31
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Topics
Abstract EN
Approximately one-third of patients with advanced, HER2+ve breast cancer (BC) develop brain metastases (BMs).
The aim of this study is to investigate efficacy and tolerability of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metastases (BCBM).
Patients and methods : Between January 2011 and January 2013, 21 patients with HER2+ve BCBM were included.
Sixteen patients (76.19 %) progressed after whole brain radiotherapy (WBRT) and 5 patients (23.81 %) were treatment-naı¨ve for BM.
Patients received lapatinib (1250 mg / day continuously) and capecitabine (2000 mg / m2 on days 1-14 of a 21-day cycle).
All patients were treated with trastuzumab either in the adjuvant or metastatic setting.
No patients had received prior lapatinib and / or capecitabine.
End-points were response rate (RR), progression free survival (PFS), overall survival (OS) and toxicity.
Results : The overall response rate (ORR) was 33.3 % (7 / 21) and all were partial response.
For patients receiving prior WBRT and patients receiving LC as first line treatment for BCBM the ORR was 31.2 % (5 / 16) and 40.0 % (2 / 5) respectively.
Median PFS was 5.5 months.
Median OS was 11 months.
Treatment-related adverse events were manageable.
Grade 3-4 toxicities were hand-foot syndrome (14.3 %), diarrhea (14.3 %), nausea / vomiting (9.5 %), mucositis (4.8 %), and skin rash (4.8 %).
Conclusion : The combination of LC is active and well-tolerated treatment in patients with HER2+ve BCBM.
American Psychological Association (APA)
Shawqi, Hanan& Tawfiq, Hisham. 2014. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer : a phase II study. Journal of the Egyptian National Cancer Institute،Vol. 26, no. 4, pp.187-194.
https://search.emarefa.net/detail/BIM-428605
Modern Language Association (MLA)
Shawqi, Hanan& Tawfiq, Hisham. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer : a phase II study. Journal of the Egyptian National Cancer Institute Vol. 26, no. 4 ( 2014), pp.187-194.
https://search.emarefa.net/detail/BIM-428605
American Medical Association (AMA)
Shawqi, Hanan& Tawfiq, Hisham. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer : a phase II study. Journal of the Egyptian National Cancer Institute. 2014. Vol. 26, no. 4, pp.187-194.
https://search.emarefa.net/detail/BIM-428605
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 193-194
Record ID
BIM-428605